Search results for "Karnofsky Performance Statu"

showing 10 items of 26 documents

Does pain intensity predict a poor opioid response in cancer patients?

2011

Abstract Aim The aim of this study was to test the hypothesis that initial pain intensity is not a predictive factor of poor opioid response in advanced cancer patients, as suggested by a recent work. Methods A secondary analysis of one-hundred-sixty-seven patients referred for treatment of cancer-related pain was conducted. Pain intensity at admission was recorded and patients were divided in three categories of pain intensity: mild, moderate and severe. Patients were offered a treatment with opioid dose titration, according to department policy. Data regarding opioid doses and pain intensity were collected after dose titration was completed. Four levels of opioid response were considered:…

MaleCancer ResearchOpioid responseopioid response in cancer patientPainOpioidSettore MED/42 - Igiene Generale E ApplicataSecondary analysisNeoplasmsmedicineHumansProspective StudiesCancer painKarnofsky Performance StatusAdverse effectAgedPain Measurementpain intensityAnalgesicsAnalysis of VarianceAssessment tools; Cancer pain; Opioid response; Aged; Analgesics Opioid; Analysis of Variance; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Cancer Research; Oncologybusiness.industryCancerMiddle Agedmedicine.diseaseAdvanced cancerIntensity (physics)Predictive factorAnalgesics OpioidAssessment toolsTreatment OutcomeOncologyOpioidAnesthesiapain intensity; opioid response in cancer patients; trial clinicoFemaletrial clinicoCancer painbusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Emergencies in patients with advanced cancer followed at home.

2012

Abstract CONTEXT: Patients with advanced cancer stay at home for most of their time, and acute problems may occur during home care. Caregivers may call medical services for an emergency, which can result in patients being admitted to the hospital. No data exist on emergencies in patients followed by a home care team. OBJECTIVES: The aim of this multicenter prospective study was to assess the frequency, reasons for, and subsequent course of emergency calls for patients followed at home by a palliative care team. METHODS: A consecutive sample of patients admitted to home care programs was surveyed for a period of seven months. Epidemiological data, and characteristics of emergency calls and o…

Malemedicine.medical_specialtyEmergency Medical ServicesPalliative careMEDLINEContext (language use)Settore MED/42 - Igiene Generale E Applicataadvanced cancer; home care; epidemiologic studypalliative care emergencyNeoplasmsEpidemiologymedicineEmergency medical servicesadvanced cancerHumansIn patientProspective StudiesKarnofsky Performance StatusProspective cohort studyNursing (all)2901 Nursing (miscellaneous)General NursingAgedpalliative carebusiness.industryemergency medical caremedicine.diseaseHome Care ServicesTelephoneAnesthesiology and Pain Medicineemergency medical care; Home care; palliative care; palliative care emergency; Aged; Caregivers; Emergency Medical Services; Female; Home Care Services; Humans; Italy; Karnofsky Performance Status; Male; Neoplasms; Prospective Studies; Telephone; Emergencies; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)CaregiversItalyepidemiologic studyEmergency medicineDeliriumFemaleNeurology (clinical)Medical emergencymedicine.symptomEmergencieshome carebusinessJournal of pain and symptom management
researchProduct

The course of symptom frequency and intensity in advanced cancer patients followed at home

2000

Four hundred consecutive patients who were referred to a home palliative care program were prospectively surveyed to estimate the prevalence and severity of common symptoms according to the changes in the performance status. Patients were admitted for the presence of different symptoms and psychosocial support. Common symptoms included in a standard form were rated for severity (absent 0, mild 1, moderate 2, severe 3) for each visit. Pain intensity was rated on a numerical scale (0-10). For each level of Karnofsky performance score (K), the frequency and the worse symptom intensity were recorded until patient's death. Data from 370 patients were analyzed. Pain was effectively controlled. In…

Malemedicine.medical_specialtyPalliative careNauseaEpidemiologyPopulationSymptomPainNeoplasmsInternal medicinemedicineHumansProspective StudiesProspective cohort studyeducationGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedPain MeasurementCancereducation.field_of_studyPerformance statusbiologybusiness.industryMiddle Agedbiology.organism_classificationHome Care ServicesDysphagiaAnesthesiology and Pain MedicineNeurologyPyrosisVomitingPhysical therapyKarnofsky performance statuPalliative careFemaleNeurology (clinical)medicine.symptombusiness
researchProduct

Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy

2007

An inverse association either between depression or impaired functional status and quality of life (QoL) has been reported for cancer patients, but the independent effect of depression or depressive symptoms and of functional impairment on QoL is unclear.We investigated the prevalence of depression or depressive symptoms with the Beck Depression Inventory (BDI), the functional impairment with the ECOG-Performance-Status (ECOG-PS) and the QoL with the EORTC-QLQ-C30 questionnaire in a sample of 175 hospitalised cancer patients prior to the start of chemotherapy.Sixteen of 175 patients (9.1%) screened positive for major depression, 29 (16.6%) had mild to moderate depressive symptoms. In 11 of …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentPsychometricsPsychometricsHealth StatusQuality of lifeNeoplasmsSurveys and QuestionnairesInternal medicinePrevalencemedicineHealth Status IndicatorsHumansRadiology Nuclear Medicine and imagingPsychological testingProspective StudiesKarnofsky Performance StatusProspective cohort studyLife StyleneoplasmsFatigueDepression (differential diagnoses)AgedAged 80 and overAnalysis of VarianceDepressive Disorder MajorPsychological TestsUnivariate analysisDepressionbusiness.industryBeck Depression InventoryCancerHematologyGeneral MedicineMiddle Agedmedicine.diseaseHealth SurveyshumanitiesOncologyQuality of LifePhysical therapyFemalebusinessActa Oncologica
researchProduct

Delirium assessed by Memorial Delirium Assessment Scale in advanced cancer patients admitted to an acute palliative/supportive care unit

2017

Background: Delirium is often unrecognized in cancer patients. The aim of this study was to investigate the prevalence of delirium assessed by the Memorial Delirium Assessment Scale (MDAS) and possible associated factors on admission to an acute palliative/supportive care unit (APSCU). The secondary outcome was to assess changes in MDAS and symptom burden at time of discharge. Methods: A consecutive sample of advanced cancer patients who were admitted to an APSCU was prospectively assessed for a period of 10 months. Patient demographics, including age, gender, primary diagnosis, Karnofsky status, stage of disease, and educational level were collected. The Edmonton Symptom Assessment Scale (…

Malemedicine.medical_specialtyPalliative careDiseaseCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineNeoplasmsAdvanced cancerparasitic diseasesmedicinePrevalenceHumans030212 general & internal medicineKarnofsky Performance StatusStage (cooking)Intensive care medicineReferral and ConsultationAgedAged 80 and overpalliative carebusiness.industryMedicine (all)edmonton symptom assessment scaleCancerDeliriummemorial delirium assessment scaleGeneral MedicineAssessment scaleLength of StayMiddle Agedmedicine.diseaseAdvanced cancerPatient DischargeHospitalization030220 oncology & carcinogenesisEmergency medicineDeliriumNeoplasmFemaleKarnofsky Performance Statumedicine.symptombusinessHuman
researchProduct

Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out

2017

Abstract Background Patient-reported outcomes are of high importance in clinical neuro-oncology. However, assessment is still suboptimal. We aimed at exploring factors associated with the probability for a) drop out of study and b) death during follow-up. Methods Patients were assessed twice during follow-up visits scheduled within 3 to 5 months of each other by using 3 validated patient-reported outcome measures (t1: first assessment, t2: second assessment). As “death” was seen as a competing risk for drop out, univariate competing risk Cox regression models were applied to explore factors associated with dropping out (age, gender, WHO grade, living situation, recurrent surgery, Karnofsky …

medicine.medical_specialtyMotor dysfunctionKarnofsky Performance Statusbusiness.industryProportional hazards modelMedicine (miscellaneous)Original Articlesmedicine.diseasehumanities03 medical and health sciences0302 clinical medicinePhysical functioning030220 oncology & carcinogenesisDrop outInternal medicineGliomamedicinePhysical therapyDistress ThermometerPatient-reported outcomebusiness030217 neurology & neurosurgeryNeuro-Oncology Practice
researchProduct

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Symptom Expression in Patients with Advanced Cancer Admitted to an Acute Supportive/Palliative Care Unit With and Without Delirium

2018

Abstract Aim The aim of this study was to investigate the relationship between delirium and symptom expression in patients with advanced cancer admitted to an acute supportive/palliative care unit (ASPCU). Methods A consecutive sample of patients with advanced cancer who were admitted to an ASPCU was prospectively assessed for a period of 10 months. The Edmonton Symptom Assessment Scale (ESAS) and the MDAS (Memorial Delirium Assessment Scale) were measured at admission (T0) and after 7 days of palliative care (T7). Results Two hundred forty-six patients had complete data regarding MDAS measurements, at either T0 and T7. Of these, 75 (30.5%) and 63 patients (25.6%) had delirium at T0 and aft…

MaleCancer Researchmedicine.medical_specialtyWeaknessPalliative careNauseaNeuropsychological TestsSeverity of Illness Indexbehavioral disciplines and activities03 medical and health sciencesCognition0302 clinical medicineAdvanced cancerNeoplasmsInternal medicinemental disordersHumansMedicineProspective Studies030212 general & internal medicineKarnofsky Performance StatusDepression (differential diagnoses)Edmonton Symptom Assessment ScaleAgedNeoplasm StagingPain MeasurementDepressionbusiness.industryPalliative CareDeliriumCancerMemorial Delirium Assessment ScaleCancer PainMiddle Agedmedicine.diseaseAdvanced cancernervous system diseasesHospitalizationTreatment OutcomeOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisBehavior Rating ScaleAnxietyDeliriumFemaleSymptom Assessmentmedicine.symptombusinessThe Oncologist
researchProduct

Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.

2014

Abstract Abstract Objective: The aim of this study was to assess the efficacy and tolerability of tapentadol (TP) for a period of 4 weeks in patients who were already treated by opioids. Methods: A convenience sample of 30 patients was selected for a prospective observational cohort study. Cancer patients who were receiving at least 60 mg of oral morphine equivalents were selected. Patients discontinued their previous opioid analgesics before starting TP, in doses calculated according the previous opioid consumption (1:3.3 ratio with oral morphine equivalents). The subsequent doses were changed according to the patients' needs for a period of 4 weeks. Oral morphine was offered as a breakthr…

MalePalliative careReceptors Opioid muAdverse effectSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsReceptorsDrug Dosage CalculationsProspective StudiesAdverse effects; Cancer pain; Palliative care; TapentadolCancer painPain MeasurementAnalgesicsMorphineMedicine (all)General MedicineMiddle AgedTapentadolAnalgesics OpioidTapentadolTreatment OutcomeItalyTolerabilityAnesthesiaPalliative careFemaleDrugDrug Monitoringmedicine.drugCohort studyAdverse effects; Cancer pain; Palliative care; Tapentadol; Aged; Analgesics Opioid; Cohort Studies; Dose-Response Relationship Drug; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Italy; Karnofsky Performance Status; Male; Middle Aged; Morphine; Neoplasms; Pain Management; Pain Measurement; Phenols; Prospective Studies; Receptors Opioid mu; Treatment Outcome; Pain; Medicine (all)PainOpioidDose-Response RelationshipPhenolsmedicineHumansPain ManagementKarnofsky Performance StatusAdverse effectAgedDose-Response Relationship DrugAdverse effectsbusiness.industryCancermedicine.diseaseOpioidmubusinessCancer pain
researchProduct

NCOG-10. FACTORS INFLUENCING NEUROCOGNITIVE FUNCTION IN PATIENTS WITH NEUROEPITHELIAL TUMORS

2017

Though cognitive function is proven to be an independent predictor of survival in patients with intrinsic brain tumors, higher cognitive functions are still seldom studied. Aim of this study was to assess neurocognitive function and to identify risk factors for neurocognitive deficits in patients with intrinsic brain tumors. 103 patients with primary neuroepithelial tumors who received tumor resections or biopsies were included in this prospective study. The following data was acquired: mini-mental state examination, preoperative tumor volume, WHO grade, tumor entity and location, and the Karnofsky performance status scale. Furthermore, patients conducted an extensive neuropsychological tes…

OncologyCancer Researchmedicine.medical_specialtyKarnofsky Performance Statusbusiness.industryNeuroepithelial tumorsRisk identificationAbstractsOncologyInternal medicinemedicineIn patientNeurology (clinical)businessCognitive impairmentNeurocognitiveNeuro-Oncology
researchProduct